What Is Rett Syndrome and Why Is It Hard to Treat?
Rett syndrome is a rare neurological disorder caused by mutations in the MECP2 gene that almost exclusively affects girls, stripping away language, movement, and independence after months of normal development. Here is what we know about its biology and the search for a cure.
A Disease That Appears, Then Destroys
For the first six to eighteen months of life, children with Rett syndrome appear entirely healthy. They reach early milestones, make eye contact, babble, and grow. Then, gradually and then rapidly, something goes wrong. Speech disappears. Purposeful hand movements are replaced by compulsive wringing or rubbing. Breathing becomes irregular. Seizures begin. What looked like a healthy toddler becomes a child with severe neurological disability — almost overnight.
Rett syndrome affects roughly 1 in 10,000 to 15,000 girls worldwide, making it one of the most common causes of severe intellectual disability in females. It is far rarer in boys, and when it does occur, it is usually fatal in infancy. The disorder was first described by Austrian physician Andreas Rett in 1966, but its genetic cause remained unknown for decades.
The MECP2 Gene: A Master Switch Gone Wrong
In 1999, scientists discovered that the overwhelming majority of Rett syndrome cases — roughly 95 percent — are caused by mutations in a single gene: MECP2, which sits on the X chromosome. The gene encodes a protein called methyl-CpG-binding protein 2, which acts as a master regulator of gene expression throughout the brain. When MECP2 functions normally, it helps neurons fine-tune which genes are active and which are silenced. When it is mutated, the result is a kind of molecular chaos in brain cells.
Because girls carry two X chromosomes, they have one functional copy of MECP2 to partially compensate — which is why they survive and develop the syndrome's characteristic pattern of partial, then lost, function. Boys, with only one X chromosome, typically cannot compensate at all.
The mutation is almost always spontaneous, arising randomly rather than being inherited from parents. Different mutations on the MECP2 gene produce different degrees of severity, which is why no two cases of Rett syndrome are identical.
Four Stages of Decline
Clinicians typically describe Rett syndrome progressing through four stages:
- Stage I (Early Onset, 6–18 months): Subtle developmental slowdown; the child stops meeting new milestones. Often missed or attributed to other causes.
- Stage II (Rapid Regression, ages 1–4): Loss of speech and hand skills. Breathing irregularities, hand-wringing, and possible seizures emerge.
- Stage III (Plateau, ages 2–10): Regression stabilizes. Patients may show renewed interest in their environment, though severe motor and communication impairments persist.
- Stage IV (Late Motor Deterioration): Progressive muscle weakness and scoliosis develop. Many patients require wheelchairs. This stage can last decades.
The Challenge of Treatment
For most of its history, Rett syndrome had no disease-specific treatment. Patients received supportive care — physiotherapy, speech therapy, anti-seizure medications — but nothing targeted the underlying biology. That changed in 2023, when the FDA approved trofinetide (Daybue), the first drug specifically indicated for Rett syndrome. It reduces some symptoms by mimicking a naturally occurring peptide that supports neuronal health, but it is not a cure.
The deeper challenge is the MECP2 gene itself. Unlike many genetic disorders where simply adding back a working copy of a gene is sufficient, MECP2 is exquisitely sensitive to dosage. Too little protein causes Rett syndrome; too much causes a separate, equally devastating disorder called MECP2 duplication syndrome. Any gene therapy must deliver exactly the right amount — a precise calibration that has made development far harder than for other rare diseases.
Two gene therapy candidates — Neurogene's NGN-401 and Taysha's TSHA-102 — are currently in Phase 1/2 clinical trials, both using novel technologies to control how much MECP2 protein is produced in treated cells.
A Promising New Direction
Research published in Science Translational Medicine in early 2026 by scientists at Texas Children's Hospital and Baylor College of Medicine revealed another approach: adjusting how the MECP2 gene is spliced to increase production of its partially functional protein forms. Using synthetic molecules to shift the balance between two variants of the protein — known as E1 and E2 — researchers improved survival, movement, and breathing in mouse models. Antisense oligonucleotide therapies, already approved for other conditions like spinal muscular atrophy, could potentially deliver similar effects in humans.
While no cure exists today, the convergence of gene therapy, RNA-based medicine, and a growing understanding of MECP2 biology means the field has never been more active. For the estimated 350,000 people living with Rett syndrome globally, that trajectory is the most meaningful progress in decades.
